Gilead Sciences Inc (GILD)

65.93
NASDAQ : Health Care
Prev Close 66.50
Day Low/High 65.75 / 66.68
52 Wk Low/High 65.38 / 103.10
Avg Volume 9.80M
Exchange NASDAQ
Shares Outstanding 1.31B
Market Cap 86.93B
EPS 10.10
P/E Ratio 6.69
Div & Yield 2.08 (3.10%)

Latest News

Gilead Presents Data At The International Liver Congress™ 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread

Gilead Presents Data At The International Liver Congress™ 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread

Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from two ongoing Phase 3 studies evaluating the safety and efficacy of daily Vemlidy ® (tenofovir alafenamide, TAF 25mg) in immune active patients...

Gilead To Present Clinical And Preclinical Data On Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress™ 2017

Gilead To Present Clinical And Preclinical Data On Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress™ 2017

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will present data from 15 abstracts on the pathogenesis and treatment of NASH this week at The International Liver Congress™ 2017 in Amsterdam.

Gilead Sciences To Release First Quarter 2017 Financial Results On Tuesday, May 2, 2017

Gilead Sciences To Release First Quarter 2017 Financial Results On Tuesday, May 2, 2017

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2017 financial results will be released on Tuesday, May 2, after the market closes.

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

Why Biotech Investors Should Worry When Their Stocks Turn Boring

Why Biotech Investors Should Worry When Their Stocks Turn Boring

Investors have turned away from biotech at a time when the sector is normally humming with presentations of new clinical data at springtime medical meetings.

Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views

Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views

Doug Kass shares his thoughts on Tesla and the second quarter.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Busting the Shorts : Cramer's 'Mad Money' Recap (Thursday 3/30/17)

Busting the Shorts : Cramer's 'Mad Money' Recap (Thursday 3/30/17)

This month's resilience in the market has a lot to do with short squeezes in big tech names.

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

Alphabet, Allergan, Ford: Doug Kass' Views

Alphabet, Allergan, Ford: Doug Kass' Views

Doug Kass shares his thoughts on Alphabet, Allergan and Ford.

Time to Call It Quits on Gilead Sciences

This position just hasn't worked for us.

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

The top 64 companies taking a trip to TheStreet's 2017 Market Bracket Challenge tournament.

Delta, Barracuda Networks, STMicroelectronics: 'Mad Money' Lightning Round

Delta, Barracuda Networks, STMicroelectronics: 'Mad Money' Lightning Round

Jim Cramer is bullish on Delta, Barracuda Networks, STMicroelectronics, UnitedHealth Group.

Deregulation and Energy Policy Can Fuel Markets: Cramer's 'Mad Money' Recap (Friday 3/17/17)

Deregulation and Energy Policy Can Fuel Markets: Cramer's 'Mad Money' Recap (Friday 3/17/17)

This week the markets fell back on earnings -- like Adobe -- and remained afloat, says Jim Cramer.

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Doug Kass shares his thoughts on Allergan, and says that Caterpillar remains purr-fect for shorting.

Google, Apple, Starbucks: Doug Kass' Views

Google, Apple, Starbucks: Doug Kass' Views

Doug Kass shares his thoughts on the state of the market, and notices that the irrational might now be rationalized.

Incyte Pops on Continued Gilead Takeout Speculation

Incyte Pops on Continued Gilead Takeout Speculation

Shares were up 8% during intraday trading.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

4 Value Stock Picks for an Elevated Market

4 Value Stock Picks for an Elevated Market

Taking from Ben Graham's playbook, this handful of stocks have reasonable valuations in an extended market.

4 Value Stock Picks for an Elevated Market

4 Value Stock Picks for an Elevated Market

Taking from Ben Graham's playbook, this handful of stocks have reasonable valuations in an extended market.

Celgene's Deep Pipeline Can Reassure Investors

Celgene's Deep Pipeline Can Reassure Investors

This biotech company is trading at a bargain compared to its peer group.

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.

See How Gilead Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How Gilead Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that Gilead Sciences, Inc. is the #45 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity.

Gilead Sciences To Present At The Barclays Global Healthcare Conference On Tuesday, March 14

Gilead Sciences To Present At The Barclays Global Healthcare Conference On Tuesday, March 14

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.

IBM, Apple, Amazon: Doug Kass' Views

IBM, Apple, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on peak housing, and also discusses Fannie Mae and Freddie Mac's recent kneecapping.